Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 431

1.

Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery.

Hunsicker O, Hessler K, Krannich A, Boemke W, Braicu I, Sehouli J, Meyer O, Pruß A, Spies C, Feldheiser A.

Transfusion. 2018 Apr 17. doi: 10.1111/trf.14627. [Epub ahead of print]

PMID:
29665067
2.

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeillinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2018 Apr 17;13(4):e0196142. doi: 10.1371/journal.pone.0196142. eCollection 2018.

3.

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.

Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P.

J Cancer Res Clin Oncol. 2018 Apr 6. doi: 10.1007/s00432-018-2637-1. [Epub ahead of print]

PMID:
29623421
4.

Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.

Sun P, Xue L, Song Y, Mao X, Chen L, Dong B, Braicu EL, Sehouli J.

Oncotarget. 2018 Jan 3;9(16):12682-12694. doi: 10.18632/oncotarget.23913. eCollection 2018 Feb 27.

5.

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F.

Bull Cancer. 2018 Mar 12. pii: S0007-4551(18)30071-7. doi: 10.1016/j.bulcan.2018.01.015. [Epub ahead of print] French.

PMID:
29544693
6.

Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.

Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R.

Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139-2. doi: 10.1016/j.ygyno.2018.02.020. [Epub ahead of print]

PMID:
29530331
7.

Laparoscopic Neuronavigation for Deep Lateral Pelvic Endometriosis: Clinical and Surgical Implications.

Chiantera V, Petrillo M, Abesadze E, Sozzi G, Dessole M, Catello Di Donna M, Scambia G, Sehouli J, Mechsner S.

J Minim Invasive Gynecol. 2018 Mar 2. pii: S1553-4650(18)30145-6. doi: 10.1016/j.jmig.2018.02.015. [Epub ahead of print]

PMID:
29501810
8.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.

9.
10.

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.

Ruan G, Ye L, Liu G, An J, Sehouli J, Sun P.

Onco Targets Ther. 2018 Jan 23;11:521-528. doi: 10.2147/OTT.S155581. eCollection 2018.

11.

EXPRESSION III: Patient´s Expectations and Preferences regarding Physician-Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J.

Ann Oncol. 2018 Feb 5. doi: 10.1093/annonc/mdy037. [Epub ahead of print]

PMID:
29415128
12.

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.

PMID:
29402501
13.

Risk factors for 30-day complications after cancer surgery in geriatric patients: a secondary analysis.

Scholtz K, Spies CD, Mörgeli R, Eckardt R, von Dossow V, Braun S, Sehouli J, Bahra M, Stief CG, Wernecke KD, Schmidt M; PERATECS Group.

Acta Anaesthesiol Scand. 2018 Apr;62(4):451-463. doi: 10.1111/aas.13067. Epub 2018 Jan 22.

PMID:
29359461
14.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
15.

[Ichthyosis uteri (psoriasis uteri) : A very rare disorder].

von Laffert M, Elezkurtaj S, Sehouli J, Barinoff J, Boschetti Grützmacher E, Arsenic R, Bläker H.

Pathologe. 2018 Jan 8. doi: 10.1007/s00292-017-0403-9. [Epub ahead of print] German.

PMID:
29313082
16.

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.

Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 5.

17.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

18.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

PMID:
29248998
19.

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.

PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017. Erratum in: PLoS One. 2018 Apr 17;13(4):e0196142.

20.

Cytoreductive surgery for ovarian cancer: quality assessment.

Brand AH, DiSilvestro PA, Sehouli J, Berek JS.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii25-viii29. doi: 10.1093/annonc/mdx448.

PMID:
29232471
21.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA; RARECARENet Working Group.

Eur J Surg Oncol. 2017 Nov 3. pii: S0748-7983(17)30947-2. doi: 10.1016/j.ejso.2017.09.025. [Epub ahead of print]

PMID:
29108961
22.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.

PMID:
29107348
23.

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).

Kischkel FC, Meyer C, Eich J, Nassir M, Mentze M, Braicu I, Kopp-Schneider A, Sehouli J.

J Ovarian Res. 2017 Oct 27;10(1):72. doi: 10.1186/s13048-017-0365-9.

24.

The growth of uterine myomas in untreated women: influence factors and ultrasound monitoring.

Armbrust R, Wernecke KD, Sehouli J, David M.

Arch Gynecol Obstet. 2018 Jan;297(1):131-137. doi: 10.1007/s00404-017-4568-5. Epub 2017 Oct 23.

PMID:
29063234
25.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

26.

Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women.

Pietzner K, Buttmann-Schweiger N, Sehouli J, Kraywinkel K.

Int J Gynecol Cancer. 2018 Jan;28(1):134-138. doi: 10.1097/IGC.0000000000001128.

PMID:
29040191
27.

The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.

Gungorduk K, Asicioglu O, Braicu EI, Almuheimid J, Gokulu SG, Cetinkaya N, Gungor T, Pakay G, Telli EU, Cuylan ZF, Toptas T, Bilgi A, Ozyurt R, Agacayak E, Ozdemir A, Yildirim N, Taskin S, Oge T, Erol O, Akman L, Turan A, Icen MS, Senol T, Ovali OI, Yucesoy B, Gungorduk O, Temizkan O, Sanci M, Simsek T, Meydanli MM, Harma M, Yasar L, Uysal AD, Karateke A, Ortac F, Ozalp SS, Sehouli J, Muallem MZ.

Anticancer Res. 2017 Oct;37(10):5609-5616.

PMID:
28982877
28.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

PMID:
28972047
29.

Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013.

Holleczek B, Sehouli J, Barinoff J.

Acta Oncol. 2018 Mar;57(3):324-330. doi: 10.1080/0284186X.2017.1360513. Epub 2017 Aug 11.

PMID:
28799431
30.

Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.

Koensgen D, Stope MB, Tuerbachova I, Bruennert D, Kohlmann T, Braicu I, Sehouli J, Denkert C, Darb-Esfahani S, Stickeler E, Sofroni D, Dahl E, Mustea A.

Gynecol Obstet Invest. 2017 Jul 22. doi: 10.1159/000479027. [Epub ahead of print]

PMID:
28738361
31.

Self-Reported Long-Term Autonomic Function After Laparoscopic Total Mesometrial Resection for Early-Stage Cervical Cancer: A Multicentric Study.

Lucidi A, Windemut S, Petrillo M, Dessole M, Sozzi G, Vercellino GF, Baessler K, Vizzielli G, Sehouli J, Scambia G, Chiantera V.

Int J Gynecol Cancer. 2017 Sep;27(7):1501-1507. doi: 10.1097/IGC.0000000000001045.

PMID:
28708791
32.

Diagnostic value of plasma NGAL and intraoperative diuresis for AKI after major gynecological surgery in patients treated within an intraoperative goal-directed hemodynamic algorithm: A substudy of a randomized controlled trial.

Hunsicker O, Feldheiser A, Weimann A, Liehre D, Sehouli J, Wernecke KD, Spies C.

Medicine (Baltimore). 2017 Jul;96(28):e7357. doi: 10.1097/MD.0000000000007357.

33.

Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.

PMID:
28691938
34.

Pain Mechanisms in Peritoneal Diseases Might Be Partially Regulated by Estrogen.

Börner C, Scheerer C, Buschow R, Chiantera V, Sehouli J, Mechsner S.

Reprod Sci. 2018 Mar;25(3):424-434. doi: 10.1177/1933719117715126. Epub 2017 Jun 29.

PMID:
28659008
35.

Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).

Jung S, Sehouli J, Chekerov R, Kluschke F, Patzelt A, Fuss H, Knorr F, Lademann J.

Support Care Cancer. 2017 Nov;25(11):3545-3549. doi: 10.1007/s00520-017-3781-x. Epub 2017 Jun 26.

PMID:
28653108
36.

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.

Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T.

Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 3.

37.

Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.

Muallem MZ, Parashkevova A, Almuheimid J, Richter R, Diab Y, Braicu EI, Sehouli J.

Anticancer Res. 2017 Jun;37(6):3157-3161.

PMID:
28551658
38.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

PMID:
28525846
39.

Pleomorphic Rhabdomyosarcoma of the Uterus - Case Report and a Systematic Review of the Literature.

Alavi S, Eckes L, Kratschell R, Taube ET, Rosseck F, Wieners G, Sehouli J.

Anticancer Res. 2017 May;37(5):2509-2514. Review.

PMID:
28476820
40.

Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review.

Muallem MZ, Henrich W, Braun T, Sehouli J, Kretzschmar L.

Anticancer Res. 2017 May;37(5):2487-2490. Review.

PMID:
28476817
41.

Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.

Taube ET, Denkert C, Sehouli J, Unger U, Kunze CA, Budczies J, Dietel M, Braicu E, Darb-Esfahani S.

Hum Pathol. 2017 Sep;67:30-36. doi: 10.1016/j.humpath.2017.03.020. Epub 2017 Apr 13.

PMID:
28414091
42.

Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.

Phelps DL, Borley JV, Flower KJ, Dina R, Darb-Esfahani S, Braicu I, Sehouli J, Fotopoulou C, Wilhelm-Benartzi CS, Gabra H, Yazbek J, Chatterjee J, Ip J, Khan H, Likos-Corbett MT, Brown R, Ghaem-Maghami S.

Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.

43.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011.

PMID:
28327917
44.

Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J; Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO).

Gynecol Oncol Res Pract. 2017 Mar 7;4:6. doi: 10.1186/s40661-017-0040-2. eCollection 2017.

45.

New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples.

Kischkel FC, Eich J, Meyer CI, Weidemüller P, Krapfl J, Yassin-Kelepir R, Job L, Fraefel M, Braicu I, Kopp-Schneider A, Sehouli J, De Wilde RL.

PeerJ. 2017 Mar 2;5:e3030. doi: 10.7717/peerj.3030. eCollection 2017.

46.

The ascites N-glycome of epithelial ovarian cancer patients.

Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V.

J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001. Epub 2017 Feb 8.

PMID:
28188862
47.

Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.

Koensgen D, Sehouli J, Belau A, Weiss M, Stope MB, Grokopf V, Eichbaum M, Ledwon P, Lichtenegger W, Zygmunt M, Köhler G, Mustea A.

Int J Gynecol Cancer. 2017 Mar;27(3):500-506. doi: 10.1097/IGC.0000000000000894.

PMID:
28187089
48.

Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al.

Harter P, Reuss A, Sehouli J, Chiva L, du Bois A.

Int J Gynecol Cancer. 2017 Feb;27(2):246-247. doi: 10.1097/IGC.0000000000000864.

PMID:
28114231
49.

Myofibroblasts Are Evidence of Chronic Tissue Microtrauma at the Endometrial-Myometrial Junctional Zone in Uteri With Adenomyosis.

Ibrahim MG, Sillem M, Plendl J, Chiantera V, Sehouli J, Mechsner S.

Reprod Sci. 2017 Oct;24(10):1410-1418. doi: 10.1177/1933719116687855. Epub 2017 Jan 17.

PMID:
28093048
50.

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A.

J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9. No abstract available.

Supplemental Content

Loading ...
Support Center